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Background-—The onset of plastic bronchitis (PB) can be debilitating in survivors of Fontan surgery. The rarity of this complication
makes designing studies to understand risk factors for PB challenging. This 2-center case-control study aimed to describe patient
outcomes and to assess the association of antecedent patient factors with PB development.
Methods and Results-—Using center registries, PB patients (n=25) were matched 1:2 to non-PB Fontans (n=43) by date of Fontan
surgery and center. The groups were compared for baseline characteristics. Association of patient characteristics with PB was
assessed using logistic regression and of potential risk factors with onset of PB using time-to-event analyses. The median time
from Fontan to PB diagnosis was 2.5 years. Overall, 12/25 PB patients died or underwent heart transplant; the median transplant-
free survival was 8.3 years after diagnosis. Factors associated with developing PB included post-surgical chylothorax (44% PB
versus 10% control; odds ratio [OR] 7.3; P=0.003), chest tube (CT) duration at stage 2 (P=0.04) and Fontan (P=0.004), and
postoperative ascites (36% PB versus 12% control; OR 4.2; P=0.003). CT drainage >13 days at Fontan was associated with earlier
PB onset (P=0.04). Early-onset PB was associated with an increased risk of death (OR 5.0; P=0.002).
Conclusions-—PB is a life-threatening disorder. A longer duration of CT drainage after surgery, chylothorax, and development of
ascites are all associated with developing PB. Understanding the pathophysiology of peri-operative complications in individual
patients and using targeted interventions may delay the onset of the PB phenotype. ( J Am Heart Assoc. 2014;3:e000865 doi:
10.1161/JAHA.114.000865)
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A s survival following congenital heart surgery has improvedfor even themost complex lesions, attention has turned to
important morbidities and their prevention and treatment. In
children who have undergone staged Fontan surgery for single
ventricle variants, plastic bronchitis (PB) is a particularly
debilitating late complication. It is characterized by the forma-
tion of large, rubbery plugs or “casts” in the tracheobronchial
tree. Previous reports suggest up to a 4% lifetime cumulative
incidence in survivors of Fontan surgery.1 The diagnosis is often
followed by repeated hospitalizations and invasive procedures
with a reported 5-year mortality as high as 50%.2 Antecedent
patient factors that predispose to developing PB have not been
defined. Similarly, knowledge of factors associated with even-
tual disease outcome is lacking. Clearly, a better understanding
of factors associated with the development and progression of
PB is important to identify Fontan patients at risk of developing
this complication.More importantly, improvedunderstandingof
PB could lead to identifying new therapeutic targets for
prevention and treatment of this complication.
The rarity of PB in survivors of Fontan surgery makes
designing studies to understand risk factors for this compli-
cation challenging. In this 2-center case-control study, we
aimed to: (1) assess the association of patient factors at the
time of earlier cardiac surgeries with the development of PB;
(2) characterize the outcomes of patients who developed PB;
and (3) assess the association of antecedent patient factors
with their outcome. Our working hypothesis was that patient
factors that suggest a more complicated postoperative course
during staged single-ventricle palliation would be associated
with the later development and outcome of PB.
Methods
This was a 2-center, case-control study designed to evaluate
risk factors for development of Fontan-associated PB. The
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study was approved by institutional review boards at both the
University of Michigan and Boston Children’s Hospital.
Subjects
We identified all patients who were status post-Fontan
surgery and were diagnosed with PB at either institution
between 1989 and 2012. Patients were matched 1:2 (or 1:1
when 2 matches were not available) with controls (defined as
Fontan patients who did not develop PB) by date of Fontan
surgery (within 1 year) and by surgical center. A diagnosis of
PB required a documented history of airway casts produced
either via bronchoscopic removal or expectoration. A Fontan
was defined as a patient with single-ventricle congenital
heart disease who had undergone a total cavopulmonary
anastomosis.
Patient Variables
A chart review was conducted to collect patient demographic,
medical and surgical history, and follow-up history. Specific
patient data reviewed included age and cardiac center at each
surgery, cardiac diagnosis, dominance of single ventricle,
requirement of aortic arch reconstruction at first surgery, type
of superior cavopulmonary anastomosis (Stage 2) and Fontan
surgery, duration (in days) of chest tubes (CT) after stage 2
and after Fontan, pre- and post-Fontan ventricular end
diastolic pressure (in mm Hg), pre- and post-Fontan pulmo-
nary artery pressure (PAP in mm Hg), pre- and post-stage 2
and Fontan venovenous collateral (VVC) vessel coil place-
ment, pre- and post-stage 2 and Fontan aortopulmonary
collateral (APC) vessel coil placement, presence of ascites
post-Fontan, a diagnosis of asthma post-Fontan, chylothorax
after any surgery, a diagnosis of systemic vein occlusion, and
a diagnosis of protein losing enteropathy (PLE).
Patient factors from birth through the immediate postop-
erative period following Fontan were analyzed to determine
associations with developing PB. The 2 groups – cases and
controls – were also examined for differences in outcomes
including heart transplant (HTx), death, and a composite
outcome of HTx and death. Factors that were significantly
associated with developing PB were analyzed to determine
associations with the time of PB onset and with time to
outcomes, as described above.
Statistical Analysis
Summary data are presented as median (interquartile range
[IQR], 25th, 75th percentile) or number (%). Variables with
>50% missing values in either group were not analyzed.
Univariate associations of clinical variables with the develop-
ment of PB were assessed using unconditional logistic
regression and odds ratios (OR) with 95% confidence intervals
(CI) were calculated. The ability to discriminate patients who
developed PB from those who did not was quantified using the
area under the receiver-operating characteristic (ROC) curve
(C-statistic). Pearson’s correlation was used to assess corre-
lation (r) between continuous variables. Kaplan-Meier time-to-
event analyses and log-rank test comparisons evaluated
temporal influence of factors on outcome.
Statistical analysis was performed using SAS statistical
software, version 9.3 (SAS Institute Inc) and GraphPad Prism,
version 6.01 (GraphPad Software Inc). All statistical tests
were 2-sided. A P value of <0.05 was deemed significant.
Results
Clinical Outcomes
A total of 25 patients with PB were identified. The median age
at diagnosis was 6.0 years (IQR 4.3, 10.7) with a median
duration between Fontan and the diagnosis of PB of 2.8 years
(IQR 1.6, 6.5). The median follow-up post-PB diagnosis was
2.5 years (IQR 0.7, 5.6). Overall, 19 patients (76%) were
treated with systemic steroids, 17 (68%) were treated with
heparin, 20 (80%) received at least one course of dornase-
alpha, and 15 (56%) received at least one course of inhaled
tissue plasminogen activator (56%). Additionally, 17 patients
(68%) had casts removed via bronchoscopy. There was no
difference in the incidence of death or HTx between patients
who required therapeutic bronchoscopy (9/17) and those not
requiring bronchoscopy (3/8) (P=0.67). In 7 patients (28%),
catheter-based fenestration creation or enlargement was
performed. In the fenestration creation/enlargement group, 1
patient had symptom resolution, 1 patient continues to have
PB symptoms, 3 patients later died, and 2 patients were later
transplanted. No significant difference in symptom resolution
was found between patients with fenestration creation/
enlargement and those who did not have an intervention
(P=1.0). A higher proportion of patients who underwent
fenestration creation/enlargement subsequently died or
underwent HTx (5/7) compared with patients without inter-
vention (7/18), although the difference was not significant
(P=0.20). Elective fenestration closure also had no significant
association with PB diagnosis.
The median transplant-free survival was 8.3 years after
diagnosis of PB (Figure 1). Eight patients died (32%). Among
those who died, the median time to death from diagnosis was
0.4 years (IQR 0.2, 0.6). Onset of PB within 1 year of Fontan
surgery was significantly associated with death, P=0.041, OR
5.0 (CI 1.1, 26.8), (Figure 2). HTx was performed in 8/25 (32%)
patients. Among the PB patients undergoing HTx, the indication
for HTx in all cases was severe PB symptoms refractory to
treatment. Early post-HTx mortality was high with 3/8 patients
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dying prior to hospital discharge in the immediate postoperative
period. One additional patient died 3.2 years after HTx. There
was resolution of PB in all patients who survived to hospital
discharge following HTx. In PB patients who died (with or
without HTx), the cause of death was due to complications of
PB, including respiratory failure +/ associated heart failure
(5/8) severe heart failure (1/8), hemoptysis with severe anoxic
brain injury (1/8), and the single exception of the patient dying
due to late HTx-related complications.
Comparison of Groups for Outcomes and Risk
Factors
Overall, 12/25 (48%) PB patients died or underwent heart
transplant compared with 2/43 (4.6%) controls (P<0.0001,
OR 18.9 (CI 3.7, 95.8)). One control patient died after
developing PLE whereas the second patient underwent HTx
after developing refractory arrhythmias and progressive heart
failure. PB patients spent a median of 42 days in the hospital
(IQR 19, 98) versus a median of 3 days (IQR 0, 17) for
controls following discharge from Fontan surgery (P<0.0001).
A comparison of characteristics with significant differences
between PB cases and controls is shown in Table. The following
factors were significantly associated with PB in univariate
analyses: CT days after stage 2 surgery, CT days after Fontan,
ascites following Fontan surgery, post-Fontan APC coil place-
ment, and chylothorax after any surgery. In addition, aortic
arch reconstruction during stage 1 surgery was borderline
significant. Several factors that approached but did not reach
statistical significance also warrant comment given the
relatively small size of the study groups and the factors’
potential clinic relevance: PB patients were more likely to be
diagnosed with asthma, more likely to have a systemic vein
thrombus, and less likely to require pre-Fontan VVC coiling. Of
note, important factors that were not associated include
gender, age at any surgery, pre-Fontan PAP, need for APC coils
at pre-Fontan cath, and Fontan type. Ventricular end-diastolic
pressures were not recorded in the majority of non-PB Fontans
and were not analyzed. In the PB cohort, the median ventricular
end-diastolic pressure was 9 mm Hg (IQR 7.5, 12).
By ROC analysis, CT duration >6 days at stage 2 (C-
statistic 0.68) and >13 days at Fontan (C-statistic 0.73)
optimally discriminated between PB and non-PB patients.
Given the potential covariance between prolonged CT duration
at stage 2, prolonged CT duration at Fontan, and ascites,
these variables were analyzed for correlation. Pairwise
correlation was negligible between CT output at either stage
and ascites (r=0.14 for stage 2, r=0.15 for Fontan). Corre-
lation between prolonged CT output at Stage 2 and Fontan
was moderate (r=0.48).
Each variable associated with PB diagnosis was evaluated
for its influence on the timing of PB development. Only chest
tube duration at Fontan was found to be significantly
associated with time-to-onset of PB; among PB patients,
those patients who had prolonged chest tube duration at
Fontan had significantly shorter freedom from PB (Figure 3).
Discussion
In this study, we analyzed patient factors associated with the
development of PB following Fontan surgery. We found that
prolonged chest tube drainage after Stage 2 and after Fontan
surgery, history of chylothorax associated with staged palli-
ation, ascites, and history of significant aorto-pulmonary
collaterals (important enough to require catheter coil occlu-
sion) are all associated with higher odds of developing PB on
Figure 1. Freedom from death and/or heart transplant (HTx) in
plastic bronchitis (PB) patients.
Figure 2. Freedom from death in plastic bronchitis (PB)
patients. Subjects are stratified by PB diagnosis <1 year or
≥1 year from Fontan palliation.
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follow-up. Furthermore, prolonged CT drainage was associ-
ated with earlier development of PB. In essence, these
findings suggest that Fontan patients who have experienced
higher morbidity in the perioperative periods of staged single
ventricular palliation are at higher long-term risk of developing
PB. Thus, the development of PB after Fontan surgery is not a
random phenomenon but is another manifestation of subop-
timal adaptation to cavopulmonary circulation. Unfortunately,
the onset of PB may not only be debilitating but – as the
results show – often leads to poor outcomes, particularly if
the onset is early after Fontan surgery. A close follow-up of
high-risk patients with a goal of optimum hemodynamics may
prevent or delay the onset of PB.
This is the first study to analyze factors associated with PB
following the Fontan palliation. Previous studies were either
descriptive, single-center studies1,3–5 or were case-series of
patients from a transplant registry so that all subjects were
already listed for heart transplant after developing PB.6 An
ideal study design to better understand rare, late-onset
complications such as PB after Fontan surgery would be to
follow a large, multicenter cohort of Fontan patients prospec-
tively. While cohort studies are considered essential in
determining the absolute risk of developing a disease for
subjects in the population (or the risk of a complication when
following a diseased cohort), they are impractical for studying
rare diseases. The resources required for studying a large
Table. Patient Characteristics
Plastic Bronchitis Non-Plastic Bronchitis Fontan P Value OR (95% CI)
Total patients 25 43
Male gender 17 (68%) 27 (63%) 0.81
Right dominant ventricle 18 (75%) 22 (51.1%) 0.061 2.86 (0.99, 9.18)
Age at 1st surgery (days) 0 (0 to 0) 0 (0 to 0) 0.48
Neonatal arch reconstruction 19 (76%) 22 (52.4%) 0.060 2.88 (1.00, 9.22)
Age at Stage 2 0.4 (0.3 to 0.6) 0.5 (0.4 to 0.6) 0.31
Stage 2 type 0.28
Bidirectional Glenn 15 (62.5%) 20 (50%)
Hemifontan 9 (37.5%) 19 (47.5%)
Other 0 1 (2.5%)
Stage 2 CT duration, days 6.5 (3 to 14) 4 (3 to 5) 0.04
Pre-Fontan PAP, mm Hg 12.1 (3.3) 11.6 (2.9) 0.58
Pre-Fontan APC coil 8 (35%) 10 (23%) 0.32
Pre-Fontan VVC coil 2 (9%) 11 (26%) 0.12 0.28 (0.04, 1.17)
Age at Fontan, y 2.4 (2 to 3) 2.4 (2 to 3.2) 0.87
Fontan type 0.74
Lateral tunnel 20 (80%) 38 (88%)
Extra-cardiac conduit 5 (20%) 3 (7%)
Other 0 2 (5%)
Fontan CT days 15 (8 to 25) 7.5 (5.5 to 12.5) 0.004
Post-Fontan Ascites 9 (36%) 5 (12%) 0.024 4.16 (1.24, 15.46)
Post-Fontan PAP* 16.5 (12 to 22) 13 (12 to 15) 0.03
Post-Fontan APC coil 13 (52%) 3 (7.3%) 0.0003 13.72 (3.71, 67.67)
Post-Fontan VVC coil 6 (24%) 8 (20%) 0.66
Chylothorax 11 (44%) 4 (10%) 0.003 7.27 (2.11, 28.88)
Asthma 8 (32%) 5 (12%) 0.085 3.50 (0.86, 15.78)
Systemic vein thrombus 8 (32%) 7 (17%) 0.15 2.35 (0.73, 7.79)
PLE 4 (16%) 2 (5%) 0.25 3.8 (0.50, 45.50)
Data presented as N (%), median (IQR), or mean (SD). APC indicates aortopulmonary collateral; CT, chest tube; OR, odds ratio; PAP, pulmonary artery pressure; PLE, protein losing
enteropathy; VVC, venovenous collateral.
*Value missing on 39% of non-plastic bronchitis patients.
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cohort for a long duration can be prohibitive. In contrast, case
control studies are efficient in detecting associations between
patient factors and rare diseases. Although such studies
cannot detect absolute measures of risk, the associations
found are insightful, particularly if they provide a plausible
framework for the disease, as the current study does.
The pathophysiology of PB is largely unknown. Several
mechanisms have been postulated including hyper secretion
of mucus due to chronically elevated systemic venous
pressures,7 thoracic lymphatic malformation or lymph leak
into the airways,3,8 low cardiac output,9,10 and an abnormal
inflammatory response.11 However, none of these has been
adequately supported with evidence. Given the association of
PB with Fontan physiology and the resolution in PB in patients
who survive heart transplant, some relationship with Fontan
physiology must exist. However, because many Fontan
patients with chronically elevated PAP do not develop PB
suggests that additional mechanisms are important. The
findings of the current study suggest an abnormality in the
production or drainage of pulmonary fluid for most patients.
Several potential sources exist and may differ among patients.
Lymphatic abnormalities have attracted the most attention.
There are reports of lymphatic derangements in some patients
with PB3,8,12,13 while others have described relief of symp-
toms with interventions expected to stop abnormal lymphatic
flow.14,15 Perhaps significant lymphatic derangement in the
presence of chronically elevated pulmonary artery pressure
and/or non-pulsatile flow leads to lymph stasis which results
in bronchial lymph leakage and cast formation. Alternatively, a
role for inflammation has been proposed both in patients with
prolonged chest tube drainage (or ascites) early after
Fontan11,16,17 and in patients with PB on follow-up.11 Perhaps
prolonged postoperative chest tube drainage identifies a
patient with a particularly pronounced or pathologic inflam-
matory response that may prompt airway cast formation at a
later date. Fontan physiology has been associated with
chronically elevated systemic inflammation,18 which in some
individuals with Fontan physiology maybe sufficient to result
in cast formation and PB. Characterizing the mechanism
associated with prolonged chest tube drainage after stage 2
palliation or after Fontan in an individual patient (abnormality
of hemodynamics versus lymphatic system versus inflamma-
tory response) may not only provide the basis for individu-
alized treatment of peri-operative complications but also for
the longer-term management to prevent or delay the onset of
PB in these patients.
Thus, a patient with prolonged chest tube drainage after
Fontan completion requires more vigilant monitoring of their
symptoms, signs, and functional status as they are at
increased risk of developing PB. Diagnostic evaluation at
the onset of PB could include assessment of hemodynamics
and other potential mechanisms such as evidence of systemic
inflammation and lymphatic abnormalities3; any significant
findings may direct subsequent treatment. Our results
demonstrate that some patients are at risk of early death
while many go on to require heart transplant. Early involve-
ment of heart failure teams to help optimize their medical
therapy and discuss heart transplant candidacy may improve
outcomes in these patients.
Limitations
This study has several limitations. First, despite the use of
registries from 2 large congenital heart centers, the sample size
is still relatively small, which may result in the study being
underpowered to detect associations. This is to be expected
considering the rare nature of this complication after Fontan
surgery. Second, matching criteria were limited to year and
center and were chosen to control for era effect, allow a
reasonable chance of finding suitable controls for most patients
while also permitting evaluation of other associations. Further,
to maintain study power, the logistic regression analyses used
were unconditional, meaning the matching parameters were
not specifically accounted for during each risk factor’s analysis.
Third, post-Fontan hemodynamic data were not available for
many controls as they had not undergone heart catheterization
since their Fontan surgery. Thus, full characterization of some
significant associations may be limited. Finally, the small
sample size precluded multivariable analysis meaning that
independent risk factors have not been demonstrated and
confounding may be present.
Conclusion
In the current era, post-Fontan PB remains a life-threatening
disorder. This study identified several factors associated with
Figure 3. Freedom from plastic bronchitis stratified by post-
Fontan CT duration. Subjects are stratified by ≤13 CT days or >13
CT days. CT indicates chest tube; PB, plastic bronchitis.
DOI: 10.1161/JAHA.114.000865 Journal of the American Heart Association 5















the development of PB in post-Fontan patients. A longer
duration of CT drainage after surgery, chylothorax, and
development of significant aortopulmonary collaterals are all
associated with subsequent development of PB. In particular,
prolonged duration of chest tube drainage at Fontan was
associated not only with developing PB but also with earlier
onset of the disease. Understanding the pathophysiology of
peri-operative complications in individual patients may allow
targeted interventions and may delay the onset of the PB
phenotype.
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